This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Eiser, A. R. Articles by Shanies, H. M. Search for Related Content PubMed PubMed Citation Articles by Eiser, A. R. Articles by Shanies, H. M. Social Bookmarking                         What's this?

Sustained Dapsone-Induced Remission of Hypocomplementemic Urticarial Vasculitis

A Case Report

Parikshit Singh, MD

Harvey M. Shanies, PhD, MD, FACA

Harvey M. Shanies, PhD, MD, FACA

Chief, Division of Pulmonary Medicine Elmhurst Hospital Center 79-01 Broadway Elmhurst, NY 11373-1329

Hypocomplementemic urticarial vasculitis (HUV) is often misdiagnosed. The response to drug therapy may be unsatisfactory, and immunosuppressive therapy may be associ ated with significant side effects. A 35-year-old patient whose condition was resistant to cyclophosphamide, corticosteroids, pentoxyphylline, cyproheptadine, sulindac, and colchicine was maintained in remission with dapsone, which may be the drug of choice for HUV. Emphysema has been reported to complicate HUV, but this is the first account of vasculitis-related emphysema with no confounding history of tobacco smoke exposure. The relationship of proteolytic injury to the pulmonary and other manifestations is considered, as is the possible role for dapsone in reducing it.

Angiology, Vol. 48, No. 11, 1019-1022 (1997)
DOI: 10.1177/000331979704801114


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?